ReviewEuropean journal of haematology2021
The hemostatic and thrombotic complications of liver disease.
Review in European journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Article
- ICMT deficiency ameliorates weight loss and mortality, but not tumor formation in a mouse model of liver cancer.Cell communication and signaling : CCS · 2026Article
- Balancing Thrombosis and Bleeding: Antithrombotic Therapy in Cirrhosis-Related Thrombocytopenia.Journal of clinical medicine · 2026Review
- When Atrial Fibrillation Meets Alcoholic Liver Cirrhosis: Can Direct Oral Anticoagulants Bridge the Therapeutic Gap?Biomedicines · 2026Review
- Sepsis induced coagulopathy (SIC): is it monolithic?Thrombosis journal · 2026Article
- Impact of severe thrombocytopenia on the safety of splenectomy in patients with cirrhosis predominantly caused by Wilson's disease.Frontiers in surgery · 2026Article
- Heat Shock Protein 47 as a Novel Predictive and Diagnostic Biomarker for Thrombosis in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Thrombin dynamics and clinical events in cirrhosis: low prothrombin conversion predicts bleeding risk.Frontiers in cell and developmental biology · 2026Article
- Article
- Article
- The association between hepatic fibrosis indicators and subclinical carotid atherosclerosis in the population with metabolic dysfunction-associated steatotic liver disease under 50 years old.Nutrition & metabolism · 2025Article
- Eryptosis in Liver Diseases: Contribution to Anemia and Hypercoagulation.Medical sciences (Basel, Switzerland) · 2025Review
- Phytonadione Utilization and the Risk of Bleeding in Chronic Liver Disease.Hospital pharmacy · 2024Article
- Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis.Journal of thrombosis and haemostasis : JTH · 2024Article
- Hematological abnormalities in liver cirrhosis.World journal of hepatology · 2024Review
- Coagulation Dysfunctions in Non-Alcoholic Fatty Liver Disease-Oxidative Stress and Inflammation Relevance.Medicina (Kaunas, Lithuania) · 2023Review
- Patient Blood Management in Liver Transplant-A Concise Review.Biomedicines · 2023Review
- Individualized Management of Coagulopathy in Patients with End-Stage Liver Disease.Diagnostics (Basel, Switzerland) · 2022Review
- Clinical predictors for thrombus progression in cirrhotic patients with untreated splanchnic vein thrombosis.Thrombosis research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Hepatic cirrhosis leads to numerous hematologic derangements resulting in a complex and tenuously rebalanced hemostatic milieu. The utility of common hematologic tests including the INR and aPTT in assessing hemostatic and thrombotic risk in patients with cirrhosis is limited, and consensus on transfusion thresholds and proper management of thrombotic complications continues to evolve. This review summarizes the pathophysiology of key derangements of hemostasis including those of platelets, von Willebrand factor, pro- and anticoagulation factors, and fibrin. Additionally, the pathogenesis, consequences, optimal management, and prevention of major thrombotic and bleeding complications in cirrhosis arte discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.